

FFR 12 2009

PTO/SB/08A (09-08)

Approved for use through 10/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

**Complete if Known**

Application Number	10/586,056
Filing Date	June 11, 2007
First Named Inventor	Elimelech ROCHLIN, et al.
Art Unit	1621
Examiner Name	Chukwuma O. Nwaonicha
Attorney Docket Number	27526U

of 1

**U.S.PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
1		US-5,220,043 A	06-15-1993	Zhengxin DONG, et al.	

**FOREIGN PATENT DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
1		JP 2004 002215 A	01-08-2004	National Institute of Advanced Industrial Science and Technology, Japan		
2		JP 2003 137894 A2	05-14-2003	National Institute of Advanced Industrial Science and Technology, Japan		
3		WO 99/41266 A1	08-19-1999	Emory University		
4		WO 95/21848 A1	08-17-1995	The United States of America, represented by the Secretary, Department of Health and Human Services		
5		WO 93/19760 A1	10-14-1993	The Biomembrane Institute		

Examiner Signature	/Chukwuma Nwaonicha/	Date Considered	04/18/2009
--------------------	----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (09-08)

Approved for use through 10/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of 2

**Complete if Known**

Application Number	10/586,056
Filing Date	June 11, 2007
First Named Inventor	Elimelech ROCHLIN, et al.
Art Unit	1621
Examiner Name	Chukwuma O. Nwaonicha

Attorney Docket Number

27526U

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
1	LORENZ, Peter et al., "Synthesis of N-Lost derivatives. II. Reaction of N-bis(2-chloroethyl)phosphoramicidic dichloride with 1-Aminopropane-2,3-diol," Archiv der Pharmazie, 1986, pp. 1023-1027, vol. 319 (11), VCH Verlagsgesellschaft mbH, Weinheim, GERMANY.		
2	RAMSTEDT, Bodil et al., "Comparison of the Biophysical Properties of Racemic and d-Erythro-N-Acyl Sphingomyelins," Biophysical Journal, September 1999, pp. 1498-1506, vol. 77 (3), Biophysical Society.		
3	KRATZER, Bernd et al., "Efficient Synthesis of Sphingosine-1-phosphate, Ceramide-1-phosphate, Lysosphingomyelin, and Sphingomyelin," Liebigs Annalen, 1995, pp. 957-963, VCH Verlagsgesellschaft mbH, Weinheim, GERMANY.		
4	ZANGLIS, Anthony et al., "The Biological Activity of Acetylated Sphingosylphosphorylcholine Derivatives," International Journal of Biochemistry & Cell Biology, 1996, pp. 63-74, vol. 28 (1), Elsevier Science Ltd., GREAT BRITAIN		
5	THOMPSON, Charles M. et al., "Synthesis, Configuration, and Chemical Shift Correlations of Chiral 1,3,2-oxazaphospholidin-2-ones derived from L-Serine," Journal of Organic Chemistry, 1990, pp. 111-116, vol. 55, American Chemical Society.		
6	HE, Zheng-Jie et al., "Synthesis of Novel Optically Active Cyclic Phospholipid Conjugates of Tegafur and Uridine starting from L-serine," Phosphorous, Sulfur and Silicon, 2000, pp. 223-232, vol. 160, Overseas Publishers Association Amsterdam N.V., MALAYSIA.		
7	BRUZIK, Karol S., "Synthesis and Spectral Properties of Chemically and Stereochemically Homogenous Sphingomyelin and its Analogues," Journal of the Chemical Society Perkin Transactions 1, 1988, pp. 423-431.		
8	DO, Un Hoi et al., "Mild Alkali-stable Phospholipids in Chicken Egg Yolks: Characterization of 1-Alkenyl and 1-Alkyl-SN-Glycero-3-Phosphoethanolamine, Sphingomyelin, and 1-Alkyl-SN-Glycero-3-Phosphocholine," Journal of Lipid Research, 1980, pp. 888-894, vol. 21.		
9	MARTIN, M.-J. et al., "Distribution of Bovine Milk Sialoglycoconjugates During Lactation," Journal of Dairy Science, 2001, pp. 995-1000, vol. 84, American Dairy Science Association.		
10	MARTIN, María-Jesús. et al., "Bovine Milk Gangliosides: Changes in Ceramide Moiety with Stage of Lactation," Lipids, 2001, pp. 291-298, vol. 36 (3), AOCS Press.		
11	BENDA, P. et al., "Testing of TKT Medium for Streptococcus agalactiae Screening in Bulk Milk Samples," Vet. Med.-Czech., 1997, pp. 71-80, vol. 42 (3).		
12	Avanti Polar Lipids Inc. Products Catalog, Edition VI, p. 58.		

13	BARENHOLZ, Yechezkel et al., "Sphingomyelin: Biophysical Aspects," Chemistry and Physics of Lipids, 1999, pp. 29-34, vol. 102.	
14	BARENHOLZ, Y. et al., "Sphingomyelins in Bilayers and Biological Membranes," Biochimica et Biophysica Acta, 1980, pp. 129-158, vol. 604, Elsevier/North-Holland Biomedical Press.	
15	BARENHOLZ, Y. et al., "A Calorimetric Study of the Thermotropic Behavior of Aqueous Dispersions of Natural and Synthetic Sphingomyelins," Biochemistry, 1976, pp. 2441-2447, vol. 15 (11).	
16	ECKHARDT, Erik R.M. et al., "Dietary Sphingomyelin Suppresses Intestinal Cholesterol Absorption by Decreasing Thermodynamic Activity of Cholesterol Monomers," Gastroenterology, 2002, pp. 948-956, vol. 122, American Gastroenterological Association.	
17	Morrison, W.R. et al., "Polar Lipids in Bovine Milk: II. Long-chain Bases, Normal and 2-Hydroxy Fatty Acids, and Isomeric CIS and TRANS Monoenoic Fatty Acids in the Sphingolipids," Biochimica et Biophysica Acta, 1970, pp. 460-467, vol. 202.	
18	Greene, T.W. et al., Protective Groups in Organic Synthesis, Second Edition, 1980, John Wiley & Sons, Inc.	

Examiner Signature	/Chukwuma Nwaonicha/	Date Considered	04/18/2009
--------------------	----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the